文献速递类风湿关节炎

活动性成分军事人员中进展至类风湿关节炎诊断的血清学生物标志物

Serologic Biomarkers of Progression Toward Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel.
PubMed 文献 · Arthritis Rheumatol · 2022-10-07

研究收集美国活动性成分军事人员血清样本,包括157例抗环瓜氨酸蛋白抗体(ACPA)血清阳性及50例ACPA血清阴性类风湿关节炎(RA)受试者、100例反应性关节炎(ReA)受试者和76例健康对照,分两阶段在独立蛋白质组学平台检测。基于诊断前6个月内样本构建分类模型,可溶性PD-1对RA分类特异性>89%、敏感性48%,8种分析物模型敏感性69%、相对ReA特异性>82%。

要点

  • 诊断前6个月内血清样本中,可溶性PD-1分类RA相对ReA特异性>89%,敏感性48%。
  • 8种分析物模型分类RA敏感性69%,相对ReA特异性>82%。
  • 血清C反应蛋白、血清淀粉样蛋白A和可溶性PD-1在血清阳性RA受试者诊断前最近时间点升高,可早至诊断前数年。

核心结论

  • 研究结果表明,使用实际诊断前6个月内采集的血清样本中一组细胞因子,可相对于健康对照和ReA病例以高特异性对即将发生的RA诊断进行分类。

研究设计与样本

  • 从美国活动性成分军事人员采集4个时间点的血清样本,包括157例ACPA血清阳性RA受试者、50例ACPA血清阴性RA受试者、100例ReA受试者和76例健康对照。
  • 队列分为2个阶段,每个阶段的样本在独立蛋白质组学平台上检测。
  • 基于诊断前6个月内获得的样本,通过单变量分析和多变量随机森林建模在每阶段的训练样本集和测试样本集上开发RA诊断分类模型。

主要发现

  • 在血清阳性RA受试者中,诊断前最近时间点观察到血清分析物升高,包括C反应蛋白水平、血清淀粉样蛋白A和可溶性程序性细胞死亡1(PD-1),可早至诊断前数年。
  • 直到诊断前6个月内的时间段之前,仅一小部分RA受试者的分析物水平高于健康对照水平的第95百分位数。
  • 使用诊断前6个月内获得的样本进行RA诊断分类时,可溶性PD-1相对ReA病例提供优越的特异性(>89%),RA分类的敏感性为48%。
  • 8种分析物模型提供优越的敏感性(69%),相对ReA病例具有可比的特异性(>82%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify a panel of serum biomarkers that could specifically identify imminent cases of rheumatoid arthritis (RA) before diagnosis. METHODS: Serum samples were collected at 4 time points from active component US military personnel, including 157 anti-citrullinated protein antibody (ACPA)-seropositive and 50 ACPA-seronegative RA subjects, 100 reactive arthritis (ReA) subjects, and 76 healthy controls. The cohorts were split into 2 phases, with samples tested on independent proteomic platforms for each phase. Classification models of RA diagnosis based on samples obtained within 6 months prior to diagnosis were developed both in univariate analyses and by multivariate random forest modeling of training sample sets and testing sample sets from each phase. RESULTS: Increases in serum analytes, including C-reactive protein levels, serum amyloid A, and soluble programmed cell death 1 (PD-1), were observed in seropositive RA subjects at the time point closest to diagnosis, up to several years before diagnosis. Only a small fraction of RA subjects had levels above the 95th percentile of healthy control levels until the time period within 6 months of diagnosis. For classification of RA diagnosis using samples obtained within 6 months prior to diagnosis, soluble PD-1 provided superior specificity compared to ReA cases (>89%), with a sensitivity of 48% for RA classification. An 8-analyte model provided superior sensitivity (69%), with comparable specificity relative to ReA (>82%). CONCLUSION: Our findings demonstrate that imminent RA diagnosis could be classified with high specificity, relative to healthy controls and ReA cases, using a panel of cytokines measured in serum samples collected within 6 months before actual diagnosis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Loza MJ, Nagpal S, Cole S, et al. Serologic Biomarkers of Progression Toward Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel. Arthritis Rheumatol. 2022. PMID: 35671369. doi:10.1002/art.42260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。